5 Investor presentation First three months of 2021 Sales growth of 7% driven by bot therapy areas Reported geographic sales split for the first quarter of 2021 DKK billion 21 Insulin GLP-1 Growth at CER 9% Other diabetes Obesity Biopharm 6% International Operations 14 3% 7 16% 14% 0 IO EMEA China RoW NAO 1 ‘Other diabetes’ is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of W Note: Unless otherwise specified, sales growth rates are at CER
Download PDF file